Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$7.95 USD
-0.16 (-1.97%)
Updated May 24, 2024 04:00 PM ET
After-Market: $7.92 -0.03 (-0.38%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.95 USD
-0.16 (-1.97%)
Updated May 24, 2024 04:00 PM ET
After-Market: $7.92 -0.03 (-0.38%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Zacks News
5 Small Drug Stocks to Buy From a Recovering Industry
by Kinjel Shah
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acrivon Therapeutics, Inc. (ACRV) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?
by Zacks Equity Research
Acrivon Therapeutics (ACRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.